Table 1 Review of studies reporting coronavirus infection in pregnant women
Author | Year | Study area | Test design | Pregnancy (n) | Age group | Virus detected in mother | Severe cases n (%) |
|---|---|---|---|---|---|---|---|
Chen [12] | 2020 | China | Retrospective | 9 | 26–40 | SARS-CoV-2 | 0 (0%) |
Zhu [26] | 2020 | Wuhan | Retrospective | 9 | 25–35 | SARS-CoV-2 | 2 (22.2%) |
Penfield [27] | 2020 | New York | Retrospective | 11 | 22–40 | SARS-CoV-2 | 5 (45.5%) |
Liu [28] | 2020 | Wuhan | Case series | 3 | 30–34 | SARS-CoV-2 | 3 (100%) |
Yan [29] | 2020 | China | Retrospective | 65 | 24–40 | SARS-CoV-2 | 8 (12.5%) |
Zhang [30] | 2020 | Wuhan | Retrospective | 16 | 24–34 | SARS-CoV-2 | 1 (6.3%) |
Pierce [31] | 2020 | US | Cohort study | 64 | n/a | SARS-CoV-2 | 64 (100%) |
Chen [32] | 2020 | Wuhan | Cross-sectional | 5 | 25–30 | SARS-CoV-2 | 0 (0%) |
Dong [33] | 2020 | Wuhan | Case report | 1 | 29 | SARS-CoV-2 | 1 (100%) |
Fan [34] | 2020 | Wuhan | Case report | 2 | 29,34 | SARS-CoV-2 | n/a |
Yang [35] | 2020 | Wuhan | Cross-sectional | 7 | n/a | SARS-CoV-2 | n/a |
Li [36] | 2020 | China | Case report | 1 | 30 | SARS-CoV-2 | 0 (0%) |
Wang [37] | 2020 | China | Case report | 1 | 28 | SARS-CoV-2 | n/a |
Cui [38] | 2020 | China | Case report | 1 | 55 | SARS-CoV-2 | 1 (100%) |
Yu [39] | 2020 | Wuhan | Retrospective | 7 | 29–34 | SARS-CoV-2 | 0 (0%) |
Zeng [40] | 2020 | Wuhan | Cohort study | 33 | n/a | SARS-CoV-2 | n/a |
Breslin [41] | 2020 | New York | Retrospective | 43 | 20–39 | SARS-CoV-2 | 6 (14.0%) |
Liu [42] | 2020 | China | Retrospective | 13 | 24–36 | SARS-CoV-2 | 2 (15.4%) |
Liu [43] | 2020 | Wuhan | Retrospective | 15 | 23–40 | SARS-CoV-2 | n/a |
Liu [44] | 2020 | Shanghai | Retrospective | 16 | 22–42 | SARS-CoV-2 | n/a |
Liu [45] | 2020 | Wuhan | Cross-sectional | 10 | 27–34 | SARS-CoV-2 | n/a |
Knight [46] | 2020 | UK | Prospective | 427 | n/a | SARS-CoV-2 | 40 |
Lokken [47] | 2020 | USA | Retrospective | 46 | 26–34 | SARS-CoV-2 | n/a |
Lumbreras [48] | 2020 | Mexico | Retrospective | 308 | 26–39 | SARS-CoV-2 | n/a |
Andrikopoulou [49] | 2020 | NewYork | Case series | 158 | n/a | SARS-CoV-2 | 34 |
MERS-CoV | |||||||
Assiri [50] | 2016 | SA | Case series | 5 | 15–45 | MERS-C0V | 5 (100%) |
Alfaraj [51] | 2019 | SA | Case series | 2 | 29, 39 | MERS-C0V | 0 |
Jeong [52] | 2017 | SK | Case report | 1 | 39 | MERS-C0V | 0 |
Park [53] | 2016 | SK | Case report | 1 | 39 | MERS-C0V | 1 (100%) |
Malik [54] | 2016 | UAE | Case report | 1 | 32 | MERS-C0V | 1 (100%) |
Payne [55] | 2014 | Jordan | Case report | 1 | 39 | MERS-C0V | 0 |
Alserehi [56] | 2016 | SA | Case report | 1 | 33 | MERS-C0V | 1 (100%) |
SARS-CoV | |||||||
Robertson [57] | 2004 | USA | Case report | 1 | 36 | SARS-CoV | 1 (100%) |
Stockman [58] | 2004 | USA | Case report | 1 | 38 | SARS-CoV | 0 |
Lam [59] | 2004 | China | Case control | 10 | 25–37 | SARS-CoV | 6 (60%) |
Wong [60] | 2004 | China | Retrospective | 12 | 24–44 | SARS-CoV | 6 (50%) |
Schneider [61] | 2004 | USA | Case report | 1 | – | SARS-CoV | 0 |
Ng [62] | 2006 | China | Retrospective | 7 | 25–34 | SARS-CoV | 3 (42.9%) |
Yudin [63] | 2005 | Canada | Case report | 1 | 33 | SARS-CoV | 0 |